Abstract
We sought to compare the combination therapy of adenosine and nitroprusside in no-reflow phenomenon during percutaneous coronary intervention. Improvement in coronary flow from no-reflow to postdrug state was evaluated. Patients who received adenosine (n = 21) were compared to ones who received the combination of adenosine and nitroprusside (n = 20) for treatment. Improvement of TIMI flow grades was higher in the group that received combined therapy (1.5 +/- 1.0 vs. 0.8 +/- 0.6; P < 0.05). Combination therapy of adenosine and nitroprusside is safe and provides better improvement in coronary flow compared to intracoronary adenosine alone in case of impaired flow during coronary interventions.
Copyright 2004 Wiley-Liss, Inc.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenosine / administration & dosage
-
Adenosine / adverse effects
-
Adenosine / therapeutic use*
-
Aged
-
Aged, 80 and over
-
Angioplasty, Balloon, Coronary
-
Combined Modality Therapy
-
Coronary Angiography*
-
Coronary Circulation / drug effects*
-
Coronary Disease / physiopathology
-
Coronary Disease / therapy
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Humans
-
Male
-
Middle Aged
-
Nitroprusside / administration & dosage
-
Nitroprusside / adverse effects
-
Nitroprusside / therapeutic use*
-
Severity of Illness Index
-
Treatment Outcome
-
Vasodilator Agents / administration & dosage
-
Vasodilator Agents / adverse effects
-
Vasodilator Agents / therapeutic use*
Substances
-
Vasodilator Agents
-
Nitroprusside
-
Adenosine